SCHEMBL9905949

SCHEMBL9905949

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC(O)CO

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.82
DGKA P23743 1/20 0.68
ADORA3 P0DMS8 2/20 0.66
NR1I2 O75469 1/20 0.66
PGR P06401 1/20 0.66
PTGS2 P35354 1/20 0.66
PDE4D Q08499 1/20 0.66
ALDH1A1 P00352 3/20 0.58
CYP3A4 P08684 1/20 0.58
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KMT2A Q03164 2/20 0.57
KDM4E B2RXH2 1/20 0.57
DUSP3 P51452 1/20 0.57
MEN1 O00255 1/20 0.57
LMNA P02545 1/20 0.57
SELP P16109 1/20 0.54
MGLL Q99685 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15451530 1.00 FAAH (0.82) FAAHDGKAADORA3NR1I2PGR
SCHEMBL29376090 0.96 FAAH (0.80) FAAHDGKAADORA3NR1I2PGR
1-Monolinolenin SCHEMBL18340460 0.94 FAAH (0.78) FAAHDGKAADORA3NR1I2PGR
SCHEMBL9905950 0.94 FAAH (0.78) FAAHDGKAADORA3NR1I2PGR
1-Monolinolenin SCHEMBL23611225 0.94 FAAH (0.78) FAAHDGKAADORA3NR1I2PGR
1-Monolinolenin SCHEMBL23611226 0.94 FAAH (0.78) FAAHDGKAADORA3NR1I2PGR
SCHEMBL13623309 0.94 FAAH (0.78) FAAHDGKAADORA3NR1I2PGR
1-Monolinolenin SCHEMBL1580284 0.94 FAAH (0.78) FAAHDGKAADORA3NR1I2PGR
SCHEMBL14520293 0.93 ADORA3 (0.71) FAAHDGKAADORA3NR1I2PGR
1-Monolinolenin SCHEMBL28213368 0.92 FAAH (0.74) FAAHDGKAADORA3NR1I2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355564-A1 CANNABINOIDS COMPOSITIONS WITH POLYUNSATURATED FATTY ACID MONOGLYCERIDES, METHODS AND USES THEREOF SCF PHARMA INC. (CA) 2023-11-09 US disclosed
US-11701337-B2 Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof SCF PHARMA INC. (CA) 2023-07-18 US disclosed
US-20220162171-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS Cellix Bio Provate Limited (IN) 2022-05-26 US disclosed
US-20220048850-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION CELLIX BIO PRIVATE LTD (IN) 2022-02-17 US disclosed
US-11225464-B2 Compositions and methods for the treatment of gastrointestinal polyps CELLIX BIO PRIVATE LIMITED (IN) 2022-01-18 US disclosed
US-10774059-B2 Compositions and methods for the treatment of inflammation CELLIX BIO PRIVATE LIMITED (IN) 2020-09-15 US disclosed
US-10774059-B2 Compositions and methods for the treatment of inflammation CELLIX BIO PRIVATE LIMITED (IN) 2020-09-15 US disclosed
US-20200190040-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS CELLIX BIO PRIVATE LIMITED (IN) 2020-06-18 US disclosed
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
WO-2008113177-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2008-09-25 WO disclosed
WO-2008098375-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11225464-B2 Compositions and methods for the treatment of gastrointestinal polyps APC, LPXN, SCNN1G FAAH 4427/4885DGKA 3873/4885ADORA3 3720/4885
US-20220048850-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION IL1B, IL36G, IL17A FAAH 747/4885DGKA 3117/4885ADORA3 1633/4885
US-10774059-B2 Compositions and methods for the treatment of inflammation IL1B, IL36G, IL17A FAAH 747/4885DGKA 3117/4885ADORA3 1633/4885
US-20230355564-A1 CANNABINOIDS COMPOSITIONS WITH POLYUNSATURATED FATTY ACID MONOGLYCERIDES, METHODS AND USES THEREOF CNR2, SGMS2, SGMS1 FAAH 4/4885DGKA 33/4885ADORA3 668/4885
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN FAAH 871/4885DGKA 40/4885ADORA3 1612/4885
US-20200190040-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS APC, LPXN, SCNN1G FAAH 4427/4885DGKA 3873/4885ADORA3 3720/4885
US-20220162171-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS APC, LPXN, SCNN1G FAAH 4427/4885DGKA 3873/4885ADORA3 3720/4885
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 FAAH 225/4885DGKA 36/4885ADORA3 2402/4885
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF PPARG, PTGES, PTGIS FAAH 267/4885DGKA 102/4885ADORA3 1724/4885
US-11701337-B2 Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof CPT2, AGK, GSR FAAH 120/4885DGKA 130/4885ADORA3 1466/4885
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN FAAH 871/4885DGKA 40/4885ADORA3 1612/4885
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 FAAH 225/4885DGKA 36/4885ADORA3 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.